^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    intismeran autogene (mRNA-4157)

    i
    Associations
    News

    Trials

    Company:
    Merck (MSD), Moderna
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) (NCT03313778)
    Phase 1
    ModernaTX, Inc.
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    08/14/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • ALK • TMB
    |
    EGFR mutation • ALK positive • ALK translocation • EGFR positive
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)